Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant factor VIIa BI
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant factor VIIa BI (also known as rFVIIa BI or BAX 817) is a recombinant protein developed as a blood coagulation factor for the treatment of hemophilia A and hemophilia B. It acts by stimulating the activity of Factor VIIa in the coagulation cascade, thereby promoting hemostasis in patients with bleeding disorders. The drug was originally developed by Baxter International and later by Shire (now part of Takeda). Its mechanism involves activation of Factor X to Xa and Factor IX to IXa via complex formation with tissue factor, leading to thrombin generation and clot formation at sites of vascular injury[8][5]. Development for hemophilia A and B was discontinued after reaching phase III clinical trials[8].
- Other names
- recombinant factor VIIa BIrFVIIa - BaxaltaBAX 817BAX817BAX-817
02
Targets
GP9 (Platelet glycoprotein ib-ix-v complex)F9 (Coagulation Factor IX)F10 (Factor Xa)F3 (Tissue factor)
Beyond the preview
Go deeper on recombinant factor VIIa BI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant factor VIIa BI.